Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 09 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Dexamethasone Tablets USP, one milligram. The approval allows Zydus to manufacture and market the medication, which is used for various medical conditions. The product will be produced at the company's facility in Baddi, Himachal Pradesh. This marks a significant addition to Zydus's portfolio, which now includes numerous approvals from the USFDA.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases